NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology
NCCN Oncology Research Program to oversee projects exploring oral medication combination targeting tumor suppression genes.
News provided by
Share this article
®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg). The NCCN ORP convened a Scientific Review Committee to review, evaluate, and select awardees and will provide oversight for the two-year studies which will commence later in 2021. Research funding will be provided by a grant from Taiho Oncology, who will also supply the decitabine and cedazuridine tablet.
March 10, 2021, by NCI Staff
The coronavirus pandemic initially led to sharp decreases in the use of cancer screening tests, such as low-dose CT scans for lung cancer.
Credit: Used with permission from the University of Cincinnati
In January, First Lady Dr. Jill Biden visited a community health clinic near the White House to learn about the impact of COVID-19 on access to preventive care, including cancer screening.
At Whitman-Walker Health, Dr. Biden learned, the coronavirus pandemic initially led to sharp decreases in the use of recommended cancer screening tests, which could mean that some early cancers may have gone undetected.
E-Mail
IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more
Credit: City of Hope
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in
The Future: How We Can Reach the “Brave New World” of Diverse and Equitable Clinical Trials, Upcoming Webinar Hosted by Xtalks
Share Article
This is the fourth webinar in a four-part series from Syneos Health® titled “Blazing a Trail to Clinical Trial Diversity”. In this free webinar, attendees will learn about potential regulatory changes that could be made to increase greater patient diversity in clinical trials and understand the benefits of inclusive trials. The featured speakers will also discuss how to reward organizations for creating truly equitable clinical trials.
The presenters explore how or if policy innovations, such as regulatory mandates and incentives, can move the industry forward as one.
E-Mail
WASHINGTON, DC - Investigators leading the Lung Cancer Master Protocol, or Lung-MAP trial, will present findings from three translational medicine studies at the 2020 World Conference on Lung Cancer, to be held online January 28-31, 2021.
The presentations will mark the first time that investigators share translational medicine insights from Lung-MAP, the first large-scale precision medicine trial in lung cancer backed by the National Cancer Institute (NCI), part of the National Institutes of Health, and the first major NCI trial to test multiple treatments, simultaneously, under one umbrella design. Since it launched in June 2014, the trial has tested 12 new lung cancer drugs. Lung-MAP has also amassed a scientifically valuable cache of data and biospecimens from 3,021 patients.